Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.070
0.00 (0.00%)
At close: Sep 17, 2025, 4:00 PM EDT
1.110
+0.040 (3.74%)
Pre-market: Sep 18, 2025, 5:26 AM EDT
Lucid Diagnostics Revenue
Lucid Diagnostics had revenue of $1.16M in the quarter ending June 30, 2025, with 19.16% growth. This brings the company's revenue in the last twelve months to $4.36M, up 14.74% year-over-year. In the year 2024, Lucid Diagnostics had annual revenue of $4.35M with 79.00% growth.
Revenue (ttm)
$4.36M
Revenue Growth
+14.74%
P/S Ratio
16.98
Revenue / Employee
$60,556
Employees
72
Market Cap
139.79M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.35M | 1.92M | 79.00% |
Dec 31, 2023 | 2.43M | 2.05M | 544.03% |
Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LUCD News
- 1 day ago - Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs - PRNewsWire
- 6 days ago - Lucid Diagnostics Announces Closing of Public Offering of Common Stock - PRNewsWire
- 7 days ago - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 8 days ago - Lucid Diagnostics Announces Proposed Public Offering of Common Stock - PRNewsWire
- 9 days ago - Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript) - Seeking Alpha
- 12 days ago - Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 - PRNewsWire
- 21 days ago - Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 - PRNewsWire
- 22 days ago - PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology - PRNewsWire